Skip to main content

FDA: Alzheimer's, Amyvid (florbetapir)

From MedPage Today:

FDA Puts Early Alzheimer's Test on Hold
By Peggy Peck, Executive Editor
MedPage Today
Published: March 18, 2011

[snip]

"The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early diagnosis of Alzheimer's disease -- until manufacturer Eli Lilly puts a training program in place, the company announced."

[snip]

Read the article.

Comments

Unknown said…
Anthony,

I am an editor at The Nerve, BU's neuroscience magazine and blog. Since we're just starting up, we are looking to create a following of readers interested in the mind and brain. Could you please add a link to our site on your blog? We'd be glad to do the same for you.

Best,
The Nerve Editors
http://blogs.bu.edu/ombs/

Popular posts from this blog

Welcome to Summer Session!

Summer Session begins next week for me. I am teaching several courses that I much enjoy: Introduction to Clinical Neuropsychology, Psychopharmacology, Cognitive, and Clinical Neuroscience. Let the sun shine and the coffee flow!

Welcome to Fall Semester!